Results 161 to 170 of about 1,288 (185)

Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis

Annals of Pharmacotherapy, 2022
Objective To review the pharmacology, efficacy, and safety of ibrexafungerp in the management of vulvovaginal candidiasis (VVC). Data Sources Literature was sought using PubMed (1966—February 2022) and EMBASE (1973—February 2022), and clinicaltrials.gov.
Kylie N. Barnes, Abigail M. Yancey, Alicia B. Forinash   +2 more
semanticscholar   +3 more sources

Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond

Expert Opinion on Drug Metabolism & Toxicology
Introduction Ibrexafungerp is a new triterpenoid antifungal agent with activity against a variety of fungal species, including Aspergillus spp. and echinocandin-resistant Candida spp.
G. Dixon, James S. Lewis, George R. Thompson   +2 more
semanticscholar   +3 more sources

Management of invasive candidiasis: A focus on rezafungin, ibrexafungerp, and fosmanogepix

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Management of invasive fungal infections is challenging with growing antifungal resistance. Broad antifungal use has resulted in greater intrinsic and acquired resistance among Candida spp.
Benjamin A August, P. Kale-Pradhan
semanticscholar   +3 more sources

Ibrexafungerp: First Approval

Drugs, 2021
Ibrexafungerp (BREXAFEMME®) is an orally active triterpenoid antifungal drug being developed by SCYNEXIS, Inc. for the treatment of fungal infections. The inhibition of β-1,3-D glucan synthetase by ibrexafungerp compromises the integrity of fungal cell walls.
Arnold Lee
semanticscholar   +3 more sources

Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor

Bioorganic & Medicinal Chemistry Letters, 2021
We previously reported medicinal chemistry efforts that identified MK-5204, an orally efficacious β-1,3-glucan synthesis inhibitor derived from the natural product enfumafungin. Further extensive optimization of the C2 triazole substituent identified 4-pyridyl as the preferred replacement for the carboxamide of MK-5204, leading to improvements in ...
James M. Apgar, Robert R. Wilkening, Dann L. Parker, Dongfang Meng, Kenneth J. Wildonger, Donald Sperbeck, Mark L. Greenlee, James M. Balkovec, Amy M. Flattery, George K. Abruzzo, Andrew M. Galgoci, Robert A. Giacobbe, Charles J. Gill, Ming-Jo Hsu, Paul Liberator, Andrew S. Misura, Mary Motyl, Jennifer Nielsen Kahn, Maryann Powles, Fred Racine, Jasminka Dragovic, Weiming Fan, Robin Kirwan, Shu Lee, Hao Liu, Ahmed Mamai, Kingsley Nelson, Michael Peel   +27 more
openaire   +2 more sources

Ibrexafungerp for the treatment of vulvovaginal candidiasis

Drugs of Today, 2022
Worldwide, effective management of vulvovaginal candidiasis (VVC) continues to serve as a major therapeutic goal with numerous unmet drug treatment challenges. After 3 decades of azole drug dominance, with few recent new antifungal agents and little progress in VVC management, the first-in-class oral triterpenoid glucan synthase inhibitor agent ...
openaire   +2 more sources

An evaluation of ibrexafungerp for the treatment of invasive candidiasis: the evidence to date

Expert Opinion on Pharmacotherapy, 2021
Invasive fungal infections, especially candidemia and invasive candidiasis, cause significant morbidity and mortality. The epidemiology of candida infections have changed dramatically due to an increase in risk factors associated with the development of infection and the emergence of resistant isolates such as C. glabrata and C. auris.
Rhonda E, Colombo, Jose A, Vazquez
openaire   +2 more sources

Ibrexafungerp for the treatment of vulvovaginal candidiasis: A systematic review and meta-analysis of randomized placebo-controlled trials.

Journal de Mycologie Médicale
INTRODUCTION Vulvovaginal candidiasis (VVC) is a prevalent fungal infection affecting millions of women globally, primarily caused by Candida species, most notably Candida albicans.
C. S. Kow, D. Ramachandram, S. S. Hasan, Kaeshaelya Thiruchelvam   +3 more
semanticscholar   +1 more source

A Phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasis.

American Journal of Obstetrics and Gynecology
BACKGROUND Recurrent vulvovaginal candidiasis develops in 5-9% of people assigned female at birth and has a serious impact on quality of life. Oral ibrexafungerp is a first-in-class, non-azole, triterpenoid antifungal approved in the United States for ...
Oluwatosin Goje, N. Azie, D. Angulo, Ryan H. Sobel, P. Nyirjesy, Jack D. Sobel   +5 more
semanticscholar   +1 more source

ΔF659 and F659S substitutions at the HS1 of FKS2 gene, along with E655A and W715L upstream and downstream substitutions, correlate with high ibrexafungerp MICs against Candida glabrata.

Clinical Microbiology and Infection, 2022
OBJECTIVES Ibrexafungerp is a new inhibitor of Candida spp glucan synthase. We previously set the ibrexafungerp wild-type upper limit (wtUL) and tentative ECOFF (t-ECOFF) against Candida glabrata.
Aina Mesquida, Judith Díaz-García, C. Sánchez-Carrillo, P. Martín-Rabadán, L. Alcalá, P. Muñoz, P. Escribano, J. Guinea   +7 more
semanticscholar   +1 more source